The buyers must already be discussing RAC IMHO and might already be doing their own due diligence on Bisantrene (off the record of course). I don't think it will last until the end of 2022, unless the current trials fall over of course.
If you currently own Keytruda (and other drugs), you really shouldn't allow yourself to not be fully aware of what Bisantrene could offer and if you don't currently own Keytruda (and other drugs) you also shouldn't allow yourself to not be fully aware of what Bisantrene could offer. Every big pharma would know what is happening here by now and are considering their moves, because that is the business they are all in. The question is when will we know about their plans?
The buyers must already be discussing RAC IMHO and might already...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |